127 related articles for article (PubMed ID: 15829245)
1. Mutation detection, interpretation, and applications in the clinical laboratory setting.
Strom CM
Mutat Res; 2005 Jun; 573(1-2):160-7. PubMed ID: 15829245
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic DHPLC Quality Assurance (DDQA): a collaborative approach to the generation of validated and standardized methods for DHPLC-based mutation screening in clinical genetics laboratories.
Schollen E; Dequeker E; McQuaid S; Vankeirsbilck B; Michils G; Harvey J; van den Akker E; van Schooten R; Clark Z; Schrooten S; Matthijs G;
Hum Mutat; 2005 Jun; 25(6):583-92. PubMed ID: 15880509
[TBL] [Abstract][Full Text] [Related]
3. [Mycobacterial tests].
Takashima T; Higuchi T
Kekkaku; 2008 Jan; 83(1):43-59. PubMed ID: 18283915
[TBL] [Abstract][Full Text] [Related]
4. DNA-based carrier screening in the Ashkenazi Jewish population.
Zhang B; Dearing L; Amos J
Expert Rev Mol Diagn; 2004 May; 4(3):377-92. PubMed ID: 15137904
[TBL] [Abstract][Full Text] [Related]
5. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing.
Li J; Makrigiorgos GM
Biochem Soc Trans; 2009 Apr; 37(Pt 2):427-32. PubMed ID: 19290875
[TBL] [Abstract][Full Text] [Related]
6. [Is the semen analysis a reliable test?].
Keel BA
Zhonghua Nan Ke Xue; 2005 Feb; 11(2):85-90. PubMed ID: 15755022
[TBL] [Abstract][Full Text] [Related]
7. Testing environment for single-gene disorders in U.S. reference laboratories.
Amos J; Gold B
Hum Mutat; 1998; 12(5):293-300. PubMed ID: 9792404
[TBL] [Abstract][Full Text] [Related]
8. Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory.
Amos J; Patnaik M
Hum Mutat; 2002 Apr; 19(4):324-33. PubMed ID: 11933187
[TBL] [Abstract][Full Text] [Related]
9. Identification of the commonest cystic fibrosis transmembrane regulator gene DeltaF508 mutation: evaluation of PCR--single-strand conformational polymorphism and polyacrylamide gel electrophoresis.
Kakavas KV; Noulas AV; Kanakis I; Bonanou S; Karamanos NK
Biomed Chromatogr; 2006 Oct; 20(10):1120-5. PubMed ID: 16708396
[TBL] [Abstract][Full Text] [Related]
10. Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis.
Mérelle ME; Scheffer H; De Jong D; Dankert-Roelse JE
Acta Paediatr; 2006 Nov; 95(11):1424-8. PubMed ID: 17062471
[TBL] [Abstract][Full Text] [Related]
11. Pitfalls of automated comparative sequence analysis as a single platform for routine clinical testing for NF1.
Messiaen LM; Wimmer K
J Med Genet; 2005 May; 42(5):e25. PubMed ID: 15863657
[No Abstract] [Full Text] [Related]
12. Carrier screening for cystic fibrosis in US genetic testing laboratories: a survey of laboratory directors.
Kaufman DJ; Katsanis SH; Javitt GH; Murphy JA; Scott JA; Hudson KL
Clin Genet; 2008 Oct; 74(4):367-73. PubMed ID: 18700896
[TBL] [Abstract][Full Text] [Related]
13. [Procedure for accurate evaluation of laboratory data and its international trends].
Kuwa K
Rinsho Byori; 2005 Jun; 53(6):531-9. PubMed ID: 16026081
[TBL] [Abstract][Full Text] [Related]
14. Molecular engineering approaches for DNA sequencing and analysis.
Bai X; Edwards J; Ju J
Expert Rev Mol Diagn; 2005 Sep; 5(5):797-808. PubMed ID: 16149881
[TBL] [Abstract][Full Text] [Related]
15. Antineutrophil cytoplasmic antibody (ANCA) testing of routine sera varies in different laboratories but concordance is greater for cytoplasmic fluorescence (C-ANCA) and myeloperoxidase specificity (MPO-ANCA).
Pollock W; Jovanovich S; Savige J
J Immunol Methods; 2009 Aug; 347(1-2):19-23. PubMed ID: 19490915
[TBL] [Abstract][Full Text] [Related]
16. Adoption of array technologies into the clinical laboratory.
Hadd AG; Brown JT; Andruss BF; Ye F; WalkerPeach CR
Expert Rev Mol Diagn; 2005 May; 5(3):409-20. PubMed ID: 15934817
[TBL] [Abstract][Full Text] [Related]
17. Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques.
Rohlin A; Wernersson J; Engwall Y; Wiklund L; Björk J; Nordling M
Hum Mutat; 2009 Jun; 30(6):1012-20. PubMed ID: 19347965
[TBL] [Abstract][Full Text] [Related]
18. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern.
Tripodi A; Peyvandi F; Chantarangkul V; Menegatti M; Mannucci PM
Thromb Haemost; 2002 Oct; 88(4):690-1. PubMed ID: 12362247
[No Abstract] [Full Text] [Related]
19. The potential of electrophoretic mobility shift assays for clinical mutation detection.
Hestekin CN; Barron AE
Electrophoresis; 2006 Oct; 27(19):3805-15. PubMed ID: 17031787
[TBL] [Abstract][Full Text] [Related]
20. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
